A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

NCT07743164 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

646

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer

Interventions

BIOLOGICAL: R-DXd
DRUG: Bevacizumab
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Gemcitabine
DRUG: Pegylated liposomal doxorubicin (PLD)

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]